• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- ​​​​​​​Vaccine remains in short supply as US monkeypox cases grow

Lance

MPH, CSP & CIT Retired, CHMM Emeritus
https://www.cidrap.umn.edu/news-per...-remains-short-supply-us-monkeypox-cases-grow

Vaccine remains in short supply as US monkeypox cases grow


Filed Under:
Monkeypox
Stephanie Soucheray | News Reporter | CIDRAP News

Jul 11, 2022

The monkeypox virus outbreak in the United States continues to grow, as the Centers for Disease Control and Prevention (CDC) lists 767 US monkeypox cases, an increase of 67. New York has the most cases, with 153, followed by California with 136 and Illinois with 91.

As cases grow, monkeypox vaccine continues to be in short supply at the local level, including in Chicago and New York, which were the first cities to receive large shipments of doses from the US government.

CDC-Mayo testing partnership


The demand for the two-dose vaccine is growing in gay communities, as most cases in the US are still being identified in men who have sex with men (MSM). The demand for testing has also increased, prompting the Centers for Disease Control and Prevention (CDC) to partner with Mayo Clinic Laboratories to begin conducting tests for the virus.

In a statement today, CDC Director Rochelle Walensky, MD, MPH, said, "The ability of commercial laboratories to test for monkeypox is an important pillar in our comprehensive strategy to combat this disease. This will not only increase testing capacity but also make it more convenient for providers and patients to access tests by using existing provider-to-laboratory networks."

The Mayo Clinic will take samples from across the country and be able to process 10,000 samples per week, similar to Labcorp, which announced it would begin processing the same number of tests last week.

Still some fear the push for testing is too late, and, in an eerie recall of the COVID-19 pandemic, a slow rollout of testing will help the disease spread more widely, experts said.

Global total surpasses 9,000


Global cases have reached 9,069. The UK Health Security Agency (UKHSA) says the country now has 1,552 confirmed monkeypox cases, 201 of which are new. Of the UK cases 1,482 have been confirmed in England.

"It's concerning that we are continuing to see the outbreak grow and we urge the public to do all they can to help us slow the spread, Meera Chand, MBBS, UKHSA director of clinical and emerging infections, said in a press statement. "If you've recently had new or multiple sexual partners, please be vigilant to the symptoms of monkeypox, and be aware that many of the cases we're seeing are finding only a single, or few, lesions."

Transmission in Europe continues to be primarily among MSM. An observational study yesterday in the Journal of Infection of 48 male monkeypox patients in Madrid reveals that 87.5% are MSM, and the most prevalent symptoms were the presence of skin lesions (93.8%), weakness (66.6%), and fever (52.1%).
 
Back
Top Bottom